Dianne Angus - Neuren Pharmaceuticals Non-Executive Independent Director

NURPF Stock  USD 13.45  0.04  0.30%   

Director

Ms. Dianne Angus is NonExecutive Independent Director of the Company. Dianne Angus is currently interim CEO of the Victorian Australian Medical Association and was formerly Chief Operating Officer of the neurological drug development company Prana Biotechnology. Dianne is also a registered Patent and Trademark Attorney. since 2018.
Tenure 6 years
Phone61 3 9092 0480
Webhttps://www.neurenpharma.com

Neuren Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.172) % which means that it has lost $0.172 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2746) %, meaning that it generated substantial loss on money invested by shareholders. Neuren Pharmaceuticals' management efficiency ratios could be used to measure how well Neuren Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

DIRECTOR Age

Anne KvernelandNovo Nordisk AS
64
William YoungVertex Pharmaceuticals
73
Stig StroebaekNovo Nordisk AS
55
Charles BakerRegeneron Pharmaceuticals
84
Susan KropfKroger Company
71
Donald WilliamsModerna
55
Marc TessierLavigneRegeneron Pharmaceuticals
58
Nora AufreiterKroger Company
61
Sylvie GregoireNovo Nordisk AS
59
Joseph GoldsteinRegeneron Pharmaceuticals
77
Stefan LorenModerna
50
Anne GatesKroger Company
61
Lloyd CarneyVertex Pharmaceuticals
56
Soeren PedersenNovo Nordisk AS
52
Arthur RyanRegeneron Pharmaceuticals
75
Thomas KoestlerNovo Nordisk AS
63
Yuchun LeeVertex Pharmaceuticals
52
Margaret McGlynnVertex Pharmaceuticals
58
Huda ZoghbiRegeneron Pharmaceuticals
63
Liselotte HyveledNovo Nordisk AS
51
Jorge MontoyaKroger Company
73
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. The company was incorporated in 2001 and is based in Camberwell, Australia. Neuren Pharmaceutica operates under Biotechnology classification in the United States and is traded on OTC Exchange. Neuren Pharmaceuticals Limited [NURPF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Neuren Pharmaceuticals Leadership Team

Elected by the shareholders, the Neuren Pharmaceuticals' board of directors comprises two types of representatives: Neuren Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neuren. The board's role is to monitor Neuren Pharmaceuticals' management team and ensure that shareholders' interests are well served. Neuren Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neuren Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Joseph Horrigan, VP of Clinical Devel. and Medical Affairs
Larry Glass, CEO, Managing Director
Bruce Hancox, Independent Non-Executive Director
James Shaw, COO
Patrick Davies, Non-Executive Independent Director
Lauren CA, CFO Sec
Richard Treagus, Executive Chairman of the Board
Jon Pilcher, CFO, Company Secretary
Jenny Harry, Non-Executive Independent Director
Dianne Angus, Non-Executive Independent Director
ACA ACA, MD CEO
Gerry Zhao, VP Devel
Liza MD, Chief Officer
Trevor Scott, Independent Non-Executive Director
Lawrence Glass, Chief Officer

Neuren Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Neuren Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Neuren Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Neuren Pharmaceuticals' short interest history, or implied volatility extrapolated from Neuren Pharmaceuticals options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuren Pharmaceuticals Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Complementary Tools for Neuren Pink Sheet analysis

When running Neuren Pharmaceuticals' price analysis, check to measure Neuren Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuren Pharmaceuticals is operating at the current time. Most of Neuren Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Neuren Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuren Pharmaceuticals' price. Additionally, you may evaluate how the addition of Neuren Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Please note, there is a significant difference between Neuren Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuren Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuren Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.